Intrinsic breast cancer subtypes defined by estrogen receptor signalling - Prognostic relevance of progesterone receptor loss

Modern Pathology

Volumn 26, Issue 9, 2013, Pages 1161-1171

  Braun, Lisa ^a   Mietzsch, Friederike ^a   Seibold, Petra ^b   Schneeweiss, Andreas ^c   Schirmacher, Peter ^a   Chang Claude, Jenny ^b   Peter Sinn, Hans ^a   Aulmann, Sebastian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

breast cancer; ER signaling; IHC4 score; immunohistochemistry; intrinsic subtypes; PR

Indexed keywords

CYTOKERATIN 14; CYTOKERATIN 5; E1A ASSOCIATED P300 PROTEIN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

AGED; BIOPSY; CARCINOMA; CELL PROLIFERATION; CLUSTER ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883879939     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.60     Document Type: Article

References (41)

1. Lin SX, Chen J, Mazumdar M, et al. Molecular therapy of breast cancer. Progress and future directions. Nat Rev Endocrinol 2010;6:485-493.
2. Chumsri S, Howes T, Bao T, et al. Aromatase, aromatase inhibitors and breast cancer. J Steroid Biochem Mol Biol 2011;125:13-22.
3. Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
4. Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874. (Pubitemid 32878711)
5. Geyer FC, Rodrigues DN, Weigelt B, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010;11:339-349.
6. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-750.
7. Jacquemir J, Charafe-Jauffret E, Monville F, et al. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009;11:R23.
8. Millar EK, Graham PH, McNeil CM, et al. Prediction of outcome of early ER\+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer 2011;105:272-280.
9. Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011;11:486.
10. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-1664.
11. Assersohn L, Salter J, Powles TJ, et al. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 2003;82:113-123. (Pubitemid 37476011)
12. Buck K, Vrieling A, Zaineddin AK, et al. Serum enterolactone and prognosis of postmenopausal breast cancer. J Clin Oncol 2011;29:3730-3738.
13. Vrieling A, Buck K, Heinz J, et al. Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res Treat 2012;136:195-207.
14. Aulmann S, Bentz M, Sinn HP. C-myc oncogene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2002;74:25-31. (Pubitemid 34734593)
15. Remmele W, Stegner HE. Vorschlag zur einheitlichen definition eines Immunreaktiven Score (IRS) fur den immunhistochemischen Ostrogenrezeptor- Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 1987; 8:138-140.
16. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795.
17. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-1747.
18. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-4278.
19. Barton S, Zabaglo L, A'Hern R, et al. Assessment of the contribution of the IHC4\+C score to decision making in clinical practice in early breast cancer. Br J Cancer 2012;106:1760-1765.
20. Jönsson G, Staaf J, Vallon-Christersson J, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010;12:R42.
21. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2006;23:7721-7735.
22. Kao KJ, Chang KM, Hsu HC, et al. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 2011;18:143.
23. Varga Z, Diebold J, Dommann-Scherrer C, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss working group of breast-and gynecopathologists. PloS One 2012;7:e37379.
24. Badve S, Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009;62:6-12.
25. Horwitz KB, McGuire WL. Predicting response to endocrine therapy in human breast cancer. A hypothesis. Science 1975;189:726-727.
26. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 1978;253:2223-2228. (Pubitemid 8328205)
27. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-588. (Pubitemid 36403572)
28. Arpino G, Weiss H, Lee AV, et al. Estrogen receptorpositive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-1261. (Pubitemid 41535366)
29. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001;276:9817-9824.
30. Faridi J, Wang L, Endemann G, et al. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003;9: 2933-2939. (Pubitemid 36993252)
31. Bardou VJ, Arpino G, Elledge RM, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-1979. (Pubitemid 46606386)
32. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62.
33. Viale G, Regan MM, Maiorano E, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846-3852. (Pubitemid 47477259)
34. Bradshaw MS, Tsai SY, Leng XH, et al. Studies on the mechanism of functional cooperativity between progesterone and estrogen receptors. J Biol Chem 1991;266:16684-16690. (Pubitemid 21907853)
35. Petz LN, Ziegler YS, Schultz JR, et al. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol 2004;88: 113-122. (Pubitemid 38482029)
36. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167.
37. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826. (Pubitemid 40051905)
38. Potter AS, Casa AJ, Lee AV. Forkhead box A1 (FOXA1) is a key mediator of insulin-like growth factor I (IGF-I) activity. J Cell Biochem 2012;113:110-121.
39. Creighton CJ. The molecular profile of luminal B breast cancer. Biologics 2012;6:289-297.
40. Ogawa Y, Moriya T, Kato Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut.off point as the predictor for endocrine therapy. Breast Cancer 2004;11:267-275.
41. Yamashita H, Yando Y, Nishio M, et al. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 2006;13:74-83.